IncobotulinumtoxinA use in aesthetic indications in daily practice: a European multicenter, noninterventional, retrospective study

Figures & data

Table 1 Patient (n=638) and physician (n=66) characteristics

	n (%)
Patient category
Sex
Male	104 (16.3)
Female	534 (83.7)
Country
Germany	315 (49.4)
UK	214 (33.5)
France	109 (17.1)
Age (years)
<18	0 (0.0)
≥18–≤30	46 (7.2)
>30–≤40	150 (23.5)
>40–≤50	209 (32.8)
>50–≤65	211 (33.1)
>65	22 (3.5)
BMIa (kg/m^2)
<18.5	13 (2.0)
≥18.5–≤25	412 (64.6)
>25–≤30	155 (24.3)
>30	25 (3.9)
Health status
Excellent	415 (65.1)
Good	203 (31.8)
Fair	20 (3.1)
Poor	0 (0.0)
Physician category
Medical specialism
Dermatologist	46 (69.7)
Plastic surgeon	10 (15.2)
Ear, nose, throat specialist	4 (6.1)
Gynecologist	2 (3.0)
Aesthetic practitioner	2 (3.0)
Other	2 (3.0)
Type of institution
Practice setting	26 (39.4)
Hospital setting	19 (28.8)
Both	21 (31.8)

Note:

a BMI data for 33 (5.2%) patients were not available.

Abbreviation: BMI, body mass index.

Table 2 Treated indicationsa

Indications	Patients, nb (%)	Documented treatment cycles, nc (%)
Glabellar frown lines	485 (76.0)	1,005 (69.9)
Crow’s feet	202 (31.7)	292 (20.3)
Horizontal forehead lines	246 (38.6)	389 (27.1)
Perioral area
Perioral lines	28 (4.4)	38 (2.6)
Chin lines	16 (2.5)	21 (1.5)
Marionette lines	21 (3.3)	24 (1.7)
Eyebrow lift	42 (6.6)	61 (4.2)
Facial asymmetry	3 (0.5)	3 (0.2)
Nasal region (nasolabial folds)	19 (3.0)	20 (1.4)
Nasal lines (“bunny lines”)	25 (3.9)	26 (1.8)
Nose lift	5 (0.8)	5 (0.4)
Masseter (square face)	1 (0.2)	2 (0.1)
Lower facial contours (“Nefertiti lift”)	1 (0.2)	1 (0.1)
Platysmal bands	6 (0.9)	6 (0.4)
Horizontal neck lines	5 (0.8)	6 (0.4)
Hyperhidrosis (excessive sweating)	32 (5.0)	71 (4.9)
Improved wound healing – frontal skin	1 (0.2)	1 (0.1)
Improved wound healing – infraorbital area	1 (0.2)	1 (0.1)

Notes:

a A patient may have been treated for more than one indication within a treatment cycle or in different treatment cycles

b patients =638

c documented treatment cycles =1,437.

Figure 1 Time intervals between incobotulinumtoxinA injections to treat glabellar frown lines.

Notes: Interval length was calculated as: date of subsequent treatment minus the date of preceding treatment. It could only be calculated for completed treatment cycles, ie, where the date of the following injection was given. This was not the case for the most recent treatment cycle with each patient. No further data are missing.

Figure 2 Dose of incobotulinumtoxinA injected to treat (A) glabellar frown lines and (B) crow’s feet.

Notes: n=1,004 for glabellar frown lines, as data were missing for one patient; n=292 for crow’s feet.

Figure 3 Physician satisfaction with incobotulinumtoxinA treatment cycles for glabellar frown lines, separated by injected dose.

Note: n=556.

Figure 4 Patient satisfaction with incobotulinumtoxinA treatment for glabellar frown lines, separated by injected dose.